Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

A COVID-19 diagnosis is no longer as frightening as it used to be, thanks to developments in treatment choices. However, a ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Jan. 17, 2025 — A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer ...